» Articles » PMID: 19147828

EML4-ALK Rearrangement in Non-small Cell Lung Cancer and Non-tumor Lung Tissues

Abstract

A fusion gene, echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK), with transforming activity has recently been identified in a subset of non-small cell lung cancer (NSCLC), but its pathogenetic, diagnostic, and therapeutic roles remain unclear. Both frequency and type of EML4-ALK transcripts were investigated by reverse transcription PCR in 120 frozen NSCLC specimens from Italy and Spain; non-neoplastic lung tissues taken far from the tumor were used as controls. In cases carrying the fusion transcript, we determined EML4-ALK gene and protein levels using fluorescence in situ hybridization, Western blotting, and immunoprecipitation. We also analyzed ALK protein levels in paraffin samples from 662 NSCLC specimens, including the 120 cases investigated in the molecular studies. EML4-ALK transcripts (variants 1 and 3) were detected in 9 of 120 NSCLC samples but were not specific for NSCLC since they were also found in non-cancerous lung tissues taken far from the tumor. Notably, no transcripts were detected in matching tumor samples from these patients. Fluorescence in situ hybridization analysis of cases expressing EML4-ALK transcripts showed that only a minority of cells harbored the EML4-ALK gene. None of these cases was found to express the EML4-ALK protein as examined by immunohistochemistry, Western blotting, and immunoprecipitation. The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for NSCLC. Our results show therefore that the causal role and value of EML4-ALK as a therapeutic target remain to be defined.

Citing Articles

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report.

Zhang Y, Li K, Wang C, Zou C, Su M Front Oncol. 2025; 14:1503262.

PMID: 39911820 PMC: 11794119. DOI: 10.3389/fonc.2024.1503262.


Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications over Three Last Centuries and in View of Three Different Drug Discovery Approaches.

Kawczak P, Feszak I, Baczek T Biomedicines. 2024; 12(9).

PMID: 39335535 PMC: 11428485. DOI: 10.3390/biomedicines12092021.


Real-World Data on Treatment Outcome of ALK-Positive Non-Small Cell Lung Cancer from an Indian Multicentric Cancer Registry.

Moharana L, Panda S, Devaraj S, Biswas G, Subudhi G, Parida P South Asian J Cancer. 2024; 13(2):114-120.

PMID: 38919656 PMC: 11196141. DOI: 10.1055/s-0043-1776290.


Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.

Wallenta Law J, Bapat B, Sweetnam C, Mohammed H, McBratney A, Izano M JCO Precis Oncol. 2024; 8:e2400075.

PMID: 38754057 PMC: 11371096. DOI: 10.1200/PO.24.00075.


Integrated Analysis Identifies Novel Fusion Transcripts in Laterally Spreading Tumors Suggestive of Distinct Etiology Than Colorectal Cancers.

Rai S, Singh M, Srivastava S J Gastrointest Cancer. 2022; 54(3):913-926.

PMID: 36480069 DOI: 10.1007/s12029-022-00881-5.


References
1.
Perner S, Wagner P, Demichelis F, Mehra R, LaFargue C, Moss B . EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008; 10(3):298-302. PMC: 2259458. DOI: 10.1593/neo.07878. View

2.
Pulford K, Lamant L, Morris S, Butler L, Wood K, Stroud D . Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997; 89(4):1394-404. View

3.
Beylot-Barry M, Groppi A, Vergier B, Pulford K, Merlio J . Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. Blood. 1998; 91(12):4668-76. View

4.
Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M . EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer. 2008; 98(9):1536-9. PMC: 2391097. DOI: 10.1038/sj.bjc.6604341. View

5.
Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P . A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood. 1997; 89(5):1483-90. View